Edesa Biotech; It Puts the Lotion on The SkinDISCLAIMER
This is in no way, shape or form, fluid and function, an analytical, qualitative or intelligent compte rendu. There is absolutely no financial advice here because the only financial advice I can give is to research, research, and research. The purpose of this analysis is to serve as an e
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.88 USD
−6.17 M USD
0.00 USD
6.07 M
About Edesa Biotech, Inc.
Sector
Industry
CEO
Pardeep Nijhawan
Website
Headquarters
Markham
Founded
2007
FIGI
BBG000R0LC72
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.
$EDSAEdesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care.
An inde
EDSA to Study Investigational Drug as Potential Rescue TheraphyEdesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment
I have a strong feeling... (EDSA)Hello everybody and happy new year! ❤
Major retest of breaking 6-7 years of channel Resistance. The retest after a very strong impulsive move out of the channel is forming a falling wedge with very tight price consolidation. Another plus about this stock is that it has a very low float. I like accu
EDSA dip buy opportunity! close to 100% retracementYesterday they knocked EDSA out of the ball park to $19! today it is close to where it started from two days prior. Great opportunity for a possible final boss round (Phase 3). Very good phase 3 results often 10x a company's stock price. EDSA is currently phase 1 and phase 2.
COVID news had EDSA
Files IND Application for Phase 2/3 COVID-19 StudyEdesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.
The company recently received expedited approval to begin the Phase 2/3 study in Canada and is seeking government grants to accel
Looks Like It's Bottoming Out.During the summer time I was beginning to notice that the price would spike after somebody visited one of my old articles that had been spammed on ihub or yahoo.
I said I had a source back October lol, and I'll just tell you the truth: it was my website. I had been receiving some unusual traffic fr
Just Have a Good Feeling About This One. **Let us say I have a source**
THIS IS FOR EXPERIENCED SMALL CAP TRADERS ONLY
They had 7,504,468 shares outstanding going by their S-3 dated August 29, 2019. The S-3 has been approved and it is for $50,000,000.
$6,363,096 in cash as of June.30th, and they reported a $1,822,837 loss over the f
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of EDSA is 2.26 USD — it has decreased by −3.41% in the past 24 hours. Watch Edesa Biotech, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Edesa Biotech, Inc. stocks are traded under the ticker EDSA.
EDSA stock has risen by 0.45% compared to the previous week, the month change is a −4.23% fall, over the last year Edesa Biotech, Inc. has showed a −48.16% decrease.
We've gathered analysts' opinions on Edesa Biotech, Inc. future price: according to them, EDSA price has a max estimate of 21.00 USD and a min estimate of 20.00 USD. Watch EDSA chart and read a more detailed Edesa Biotech, Inc. stock forecast: see what analysts think of Edesa Biotech, Inc. and suggest that you do with its stocks.
EDSA reached its all-time high on Aug 28, 2014 with the price of 6,934.24 USD, and its all-time low was 1.55 USD and was reached on Dec 20, 2024. View more price dynamics on EDSA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EDSA stock is 4.46% volatile and has beta coefficient of 0.32. Track Edesa Biotech, Inc. stock price on the chart and check out the list of the most volatile stocks — is Edesa Biotech, Inc. there?
Today Edesa Biotech, Inc. has the market capitalization of 15.87 M, it has increased by 1.57% over the last week.
Yes, you can track Edesa Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
Edesa Biotech, Inc. is going to release the next earnings report on May 9, 2025. Keep track of upcoming events with our Earnings Calendar.
EDSA earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.31 USD resulting in a −54.84% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about Edesa Biotech, Inc. earnings.
Edesa Biotech, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
EDSA net income for the last quarter is −1.62 M USD, while the quarter before that showed −962.05 K USD of net income which accounts for −68.10% change. Track more Edesa Biotech, Inc. financial stats to get the full picture.
No, EDSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 16 employees. See our rating of the largest employees — is Edesa Biotech, Inc. on this list?
Like other stocks, EDSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Edesa Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Edesa Biotech, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Edesa Biotech, Inc. stock shows the sell signal. See more of Edesa Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.